Gene expression of proteolytic systems and growth regulators of skeletal muscle in horses with myopathy associated with pituitary pars intermedia dysfunction

American Journal of Veterinary Research

Volumn 71, Issue 6, 2010, Pages 664-670

  Aleman, Monica ^a   Nieto, Jorge E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CALPAIN; CALPAIN 2; CASPASE; CASPASE 3; CATHEPSIN; CATHEPSIN D; COMPLEMENTARY DNA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYOSTATIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; CYTOKINE; MESSENGER RNA; PEPTIDE HYDROLASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; GENE EXPRESSION; HORSE; HOUSEKEEPING GENE; HYPOPHYSIS INTERMEDIATE LOBE; MUSCLE BIOPSY; MUSCLE GROWTH; MYOPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; RNA PROCESSING; SKELETAL MUSCLE; VALIDATION PROCESS; ANIMAL; ANIMAL DISEASE; BIOPSY; BIOSYNTHESIS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HORSE DISEASE; MALE; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA; EQUIDAE;

ANIMALS; BIOPSY; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HORSE DISEASES; HORSES; MALE; MUSCLE, SKELETAL; MYOSTATIN; PEPTIDE HYDROLASES; PITUITARY GLAND, INTERMEDIATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 77954080863     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.6.664     Document Type: Article

References (42)

1. Schott HC II. Pituitary pars intermedia dysfunction: equine Cushing's disease. Vet Clin North Am Equine Pract 2002;18:237-270.
2. McFarlane D. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. Ageing Res Rev 2007;6:54-63.
3. McFarlane D, Dybdal N, Donaldson MT, et al. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol 2005;17:73-80.
4. McFarlane D, Cribb AE. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses. Am J Vet Res 2005;66:2065-2072.
5. Millington WR, Dybdal NO, Dawson R Jr, et al. Equine Cushing's disease: differential regulation of beta-endorphin processing in tumors of the intermediate pituitary. Endocrinology 1988;123:1598-1604.
6. McFarlane D, Beech J, Cribb A. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants. Domest Anim Endocrinol 2006;30:276-288.
7. Aleman M, Watson JL, Williams DC, et al. Myopathy in horses with pituitary pars intermedia dysfunction (Cushing's disease). Neuromuscul Disord 2006;16:737-744.
8. Dybdal NO, Hargreaves KM, Madigan JE, et al. Diagnostic testing for pituitary pars intermedia dysfunction in horses. J Am Vet Med Assoc 1994;204:627-632.
9. Rose M, Griggs R. Endocrine disorders and myopathic molecules. In: Karpati G, ed. Structural and molecular basis of skeletal muscle diseases. Los Angeles: UCLA Medical Center, 2002;270-273.
10. 2+-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005;37:2134-2146.
11. Bartoli M, Richard I. Calpains in muscle wasting. Int J Biochem Cell Biol 2005;37:2115-2133.
12. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 2004;287:C834-C843.
13. Childs SG. Muscle wasting. Orthop Nurs 2003;22:251-257.
14. Moylan JS, Reid MB. Oxidative stress, chronic disease, and muscle wasting. Muscle Nerve 2007;35:411-429.
15. Powers SK, Kavazis AN, McClung JM. Oxidative stress and disuse muscle atrophy. J Appl Physiol 2007;102:2389-2397.
16. Keen JA, McLaren M, Chandler KJ, et al. Biochemical indices of vascular function, glucose metabolism and oxidative stress in horses with equine Cushing's disease. Equine Vet J 2004;36:226-229.
17. Donaldson MT, McDonnell SM, Schanbacher BJ, et al. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. J Vet Intern Med 2005;19:217-222.
18. Colahan PT, Kollias-Baker C, Leutenegger CM, et al. Does training affect mRNA transciption for cytokine production in circulating leucocytes? Equine Vet J Suppl 2002;(34):154-158.
19. Nieto JE, Aldridge BM, Beldomenico PM, et al. Characterization of equine intestinal fatty acid binding protein and its use in managing horses with colic. Am J Vet Res 2005;66:223-232.
20. Bogaert L, Van Poucke M, De Baere C, et al. Selection of a set of reliable reference genes for quantitative real-time PCR in normal equine skin and in equine sarcoids. BMC Biotechnol [serial online]. 2006;6:24. Available at: www.biomedcentral.com/1472-6750/6/24. Accessed Jan 4, 2009.
21. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:34.1-34.11.
22. Tellmann G. Application notes. The E-method: a highly accurate technique for gene expression analysis. Nat Methods 2006;3(7):i-ii.
23. McGinn MJ, Kelley BJ, Akinyi L, et al. Biochemical, structural, and biomarker evidence for calpain-mediated cytoskeletal change after diffuse brain injury uncomplicated by contusion. J Neuropathol Exp Neurol 2009;68:241-249.
24. Huang J, Forsberb N. Role of calpain in skeletal muscle protein degradation. Proc Natl Acad Sci U S A 1998;95:12100-12105.
25. Elce JS, Hegadorn C, Arthur JS. Autolysis, Ca2+ requirement, and heterodimer stability in m-calpain. J Biol Chem 1997;272:11268-11275.
26. Haddad F, Roy RR, Zhong H, et al. Atrophy responses to muscle inactivity. II. Molecular markers of protein deficits. J Appl Physiol 2003;95:791-802. (Pubitemid 36944305)
27. Du J, Wang Y, Hunter R, et al. Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A 2009;106:3543-3548.
28. Zamzami N, Marzo I, Susin SA, et al. The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition. Oncogene 1998;16:1055-1063.
29. Murphy AN, Bredesen DE, Cortopassi G, et al. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci U S A 1996;93:9893-9898.
30. Williams AB, Decourten-Myers GM, Fischer JE, et al. Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. FASEB J 1999;13:1435-1443.
31. Attaix D, Ventadour S, Codran A, et al. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 2005;41:173-186.
32. Ventadour S, Attaix D. Mechanisms of skeletal muscle atrophy. Curr Opin Rheumatol 2006;18:631-635.
33. Wang X, Hu Z, Hu J, et al. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006;147:4160-4168.
34. Tiley HA, Geor RJ, McCutcheon LJ. Effects of dexamethasone administration on insulin resistance and components of insulin signaling and glucose metabolism in equine skeletal muscle. Am J Vet Res 2008;69:51-58.
35. van der Kolk JH, Wensing T, Kalsbeek HC, et al. Laboratory findings of equine pituitary pars intermedia adenoma. Domest Anim Endocrinol 1995;12:35-39.
36. Reeves HJ, Lees R, McGowan CM. Measurement of basal serum insulin concentration in the diagnosis of Cushing's disease in ponies. Vet Rec 2001;149:449-452.
37. Carpenter S, Karpati G. Sporadic diseases of skeletal muscle. In: Carpenter S, Karpati G, eds. Pathology of skeletal muscle. 2nd ed. New York: Oxford University Press, 2001;525-629.
38. McClung JM, Judge AR, Talbert EE, et al. Calpain-1 is required for hydrogen peroxide-induced myotube atrophy. Am J Physiol Cell Physiol 2009;296:C363-C371.
39. Elbein SC, Wang X, Karim MA, et al. Role of a proline insertion in the insulin promoter factor 1 (IPF1) gene in African Americans with type 2 diabetes. Diabetes 2006;55:2909-2914.
40. Shen HM, Tergaonkar V. NFB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009;14:348-363.
41. Du J, Mitch WE, Wang Y, et al. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B. J Biol Chem 2000;275:19661-19666.
42. Ma K, Mallidis C, Bhasin S, et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003;285:E363-E371.